EP3601239
NÝJAR HETERÓSÝKLÍSKAR AFLEIÐUR SEM ERU GAGNLEGAR SEM SHP2 HEMLAR
:
EP einkaleyfi í gildi á Íslandi:
23.3.2018:
31.7.2024:
18770877.1
:
13.9.2024:
15.10.2024
:
22.3.2038:
22.3.2026:
31.3.2026
:
NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
23.3.2018
31.7.2024
13.9.2024
15.10.2024
22.3.2026
:
Jacobio Pharmaceuticals Co., Ltd.:
Unit 2, Building 5, BYBP No.88 Kechuang Street 6th Business Development Area Daxing, Beijing 101111, CN
:
MA, Cunbo:
Beijing 101111, CN
:
GAO, Panliang:
Beijing 101111, CN
:
HU, Shaojing:
Beijing 101111, CN
:
XU, Zilong:
Beijing 101111, CN
:
HAN, Huifeng:
Beijing 101111, CN
:
WU, Xinping:
Beijing 101111, CN
:
KANG, Di:
Beijing 101111, CN
:
G.H. Sigurgeirsson ehf.:
Borgartúni 26, 105, Reykjavík,
:
PCT/IB2017/051690:
23.3.2017:
WO
:
IB2018051973:
23.3.2018
:
C07D 401/14, C07D 491/107, C07D 495/10, C07D 471/20, A61K 31/497, A61P 35/00, C07D 405/14, C07D 491/113, C07D 491/20, C07D 513/10, C07F 9/6558, C07D 471/10
: 8
: 18.3.2025
: 22.3.2026
: Árnason Faktor ehf.